An interventional study of Health Education and Health Promotion and Education in Breast Carcinoma and Lung Carcinoma, sponsored by Jonsson Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-10.
Sponsored by Jonsson Comprehensive Cancer Center · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center — 7 open to participants now, 11 under way, none of them phase 3. Breast Neoplasms · Jonsson Comprehensive Cancer Center.
Among the 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center, this one is the 2nd largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2023, is one of 12 with no phase, reaches primary completion later than 7 of the 10 other live ones, and was the 40th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →7 of the 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center are open now, in 1 country. Recruiting first, the newest first:
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
Jonsson Comprehensive Cancer Center · Sites in United States
Women only
Jonsson Comprehensive Cancer Center · Sites in United States
Women only
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 16 · Phase 3 2 · Phase 4 2
First in 1997; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 42 across the 37 interventional studies, 27 across the 3 observational. Of the 30 that completed or were terminated, 4 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
Jonsson Comprehensive Cancer Center is the lead sponsor of 398 studies on the registry; 66 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 2 (5%) have results posted.
5 of the studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04553770Jonsson Comprehensive Cancer CenterTrastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | 2026-12-31 |
| NCT06387173Jonsson Comprehensive Cancer CenterRegistry of Patients Undergoing Cryoablation for Early Stage Breast Cancer | 2027-01-03 |
| NCT04297020Jonsson Comprehensive Cancer CenterBrain Health in Breast Cancer Survivors | 2027-03-15 |
| NCT05319873Jonsson Comprehensive Cancer CenterRibociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | 2027-04-01 |
| NCT05595499Jonsson Comprehensive Cancer CenterFisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors | 2027-08-14 |
Add all 5 to your calendar (.ics) → With an account.
Among the 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial assesses the use of advocates and supporters of breast and lung cancer screening to increase lung cancer screening rates amongst eligible participants. Imaging-based cancer screening is utilized with variable frequency. Breast cancer screening with mammography has been widely accepted and is commonly used among eligible women. Lung screening with computed tomography scans is poorly used, despite the potential to decrease deaths from lung cancer. There are many reasons lung screening isn't being used when compared to breast screening, such as smoking stigma and fear, along with a lack of awareness of lung screening. By conducting this trial, researchers want to assess the effectiveness of advocates and supporters of breast and lung screening, and to learn about the psychological barriers to cancer screening, identifying those that are unique to lung screening.
PRIMARY OBJECTIVES:
I. Determine the number of patients undergoing breast screening who are eligible to participate in lung screening.
II. Determine whether patients currently participating in cancer screening (breast OR lung) are successful as "cancer screening advocates." III. Determine whether laypersons who are aware of screening (including those who accompany friends and family members to their screening appointments) are successful as "cancer screening advocates." IV. Identify knowledge base and psychological barriers to screening through surveys of potential screening participants.
OUTLINE:
Participants access an electronic patient portal with educational materials at baseline, 1- and 2-year follow-ups, and also interact with a patient navigator on study. Patients also receive materials to share with their friends/family on benefits of breast and lung cancer screening on study.
After completion of study intervention, participants are followed up yearly for up to 3 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age:
Exclusion Criteria:
Age:
Participants access an electronic patient portal with educational materials at baseline, 1- and 2-year follow-ups, and also interact with a patient navigator on study. Patients also receive materials to share with their friends/family on benefits of breast and lung cancer screening on study.
Behavioral: Health Education · Other: Health Promotion and Education · Behavioral: Patient Navigation · Other: Survey Administration
Access electronic patient portal with educational material
Receive materials on breast/lung cancer screening
Interact with a patient navigator
Also known as: Patient Navigator Program
Ancillary studies
Increased rates of lung and breast cancer screening adherence
By following up with patients over the defined study period and assessing whether they obtained an incidence screen completed at one-year +/- 3 months from the recommended time. Will also measure the rates of survey completion by consented participants, the number of clicks and time spent reviewing educational materials, and the number of new participants who contacted the program through a referral by another participant.
Time frame: Up to 3 years
Success of "sphere of influence" model
Considered successful if increased lung cancer screening referrals are a direct result of women receiving screening mammograms inviting and educating friends and family about lung cancer screening.
Time frame: Up to 3 years
Started Jul 2023 (actual). Primary completion is estimated for Sep 2028, 62 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 62 months is above that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jonsson Comprehensive Cancer Center →